Clinical Trial Update: Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial update for YL-15293 in patients with advanced solid tumors harboring KRAS mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kras-mutant Cancer
• Solid Tumor

Drugs mentioned

• YL-15293

Snippet

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: UNKNOWN